Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29219903 | 0.71 | — | — | |
| SCHEMBL14877067 | 0.71 | — | — | |
| SCHEMBL2135152 | 0.71 | — | — | |
| SCHEMBL766361 | 0.71 | — | — | |
| SCHEMBL27339550 | 0.71 | — | — | |
| SCHEMBL22306362 | 0.70 | LMNA (0.43) | ALDH1A1GAATDP1LMNAPOLB | |
| SCHEMBL11749020 | 0.69 | ALDH1A1 (0.57) | ALDH1A1GAACYP2D6SLC1A3SLC1A2 | |
| SCHEMBL11820582 | 0.68 | ALDH1A1 (0.49) | ALDH1A1GAACYP2D6SLC1A3SLC1A2 | |
| SCHEMBL5483670 | 0.68 | — | — | |
| SCHEMBL9463645 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| EP-1995330-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1975256-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1944310-A2 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7368549-B2 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7045610-B2 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060009628-A1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | ELITECHGROUP, INC. | 2006-01-12 | — | — | US | disclosed |
| US-20060003349-A1 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| US-6949367-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| CN-1633436-A | Pyrrolopyrimidine derivatives | TEIJIN LTD (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6683173-B2 | CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER | EPOCH BIOSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030235822-A1 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | EPOCH BIOSCIENCES, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030224359-A1 | TMLEVELING METHODS | EPOCH BIOSCIENCES, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003349-A1 | Tm leveling compositions | RNGTT, TYMS, NT5C3B | ALDH1A1 4090/4885GAA 2953/4885CYP2D6 2257/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | ALDH1A1 3411/4885GAA 2072/4885CYP2D6 1964/4885 |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | ALDH1A1 2709/4885GAA 2655/4885CYP2D6 1375/4885 |
| US-20060009628-A1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | MSH2, RNGTT, DCLRE1B | ALDH1A1 2605/4885GAA 2535/4885CYP2D6 2482/4885 |
| US-20030224359-A1 | TMLEVELING METHODS | PTBP3, RNGTT, DTYMK | ALDH1A1 3283/4885GAA 3242/4885CYP2D6 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.